scholarly journals Once‐Daily Quadruple‐Drug Therapy with Adefovir Dipivoxil, Lamivudine, Didanosine, and Efavirenz in Treatment‐Naive Human Immunodeficiency Virus Type 1–Infected Patients

2002 ◽  
Vol 186 (7) ◽  
pp. 1028-1033 ◽  
Author(s):  
Gail Skowron ◽  
Daniel R. Kuritzkes ◽  
Melanie A. Thompson ◽  
Kathleen E. Squires ◽  
S. Diane Goodwin ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Therapy ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Adefovir Dipivoxil ◽  
Once Daily ◽  
Immunodeficiency Virus ◽  
Treatment Naïve

scholarly journals Adherence and virologic outcomes among treatment-naïve veteran patients with human immunodeficiency virus type 1 infection

Medicine ◽  
2018 ◽  
Vol 97 (2) ◽  
pp. e9430 ◽  
Author(s):  
Yan Cheng ◽  
Brian Sauer ◽  
Yue Zhang ◽  
Nancy A. Nickman ◽  
Christine Jamjian ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Immunodeficiency Virus ◽  
Treatment Naïve

A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection

2019 ◽  
Vol 71 (5) ◽  
pp. 1255-1262 ◽  
Author(s):  
Edwin DeJesus ◽  
Sara Harward ◽  
Roxanne C Jewell ◽  
Mark Johnson ◽  
Etienne Dumont ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Second Generation ◽  
Proof Of Concept ◽  
Once Daily ◽  
Immunodeficiency Virus ◽  
Maturation Inhibitor ◽  
Hiv 1

Abstract Background GSK2838232 is a second-generation, potent, small-molecule, oral human immunodeficiency virus type 1 (HIV-1) maturation inhibitor for once-daily administration boosted with a pharmacoenhancer. Methods The phase 2a, proof-of-concept study was an open-label, adaptive dose-ranging design. Safety, pharmacokinetics, and efficacy of GSK2838232 boosted by cobicistat were evaluated in individuals with HIV-1 infection. The study participants (N = 33) received GSK2838232 once daily across a range of doses (20–200 mg) with cobicistat 150 mg for 10 days. Results GSK2838232 was safe and well tolerated with no clinically meaningful changes in safety parameters or adverse events. Exposure (maximum concentration and area under the concentration-time curve from time zero to the concentration at 24 hours postdose) increased 2- to 3-fold with repeated dosing in an approximately dose-proportional manner, reaching steady-state by day 8 with a half-life (t½) from 16.3 to 19.2 hours. Clearance and t½ values were not dependent on dose. Viral load declined from baseline with all GSK2838232 doses. Mean maximum declines from baseline to day 11 in HIV-1 RNA log10 copies/mL with the 20-mg, 50-mg, 100-mg, and 200-mg cohorts were −0.67, −1.56, −1.32, and −1.70, respectively. CD4+ cell counts increased at doses ≥50 mg. Conclusions GSK2838232 with cobicistat was well tolerated and exhibited efficacy as a short-term monotherapy in participants with HIV-1. This positive proof-of-concept study supports the continued development of GSK2838232 for the treatment of HIV as part of combination antiretroviral therapy. Clinical Trials Registration NCT03045861.

scholarly journals Prevalence of Drug Resistance in Human Immunodeficiency Virus Type 1-Infected Treatment-Naive Children in Pune, India

2014 ◽  
Vol 30 (3) ◽  
pp. 294-298 ◽  
Author(s):  
Mukesh Kumar ◽  
Sourav Sen ◽  
Rakesh K. Gupta ◽  
Devidas Chaturbhuj ◽  
Srikanth P. Tripathy ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Immunodeficiency Virus ◽  
Treatment Naïve
Sign in / Sign up

Export Citation Format

Share Document